Publications by authors named "Irene Zarcos Pedrinaci"

Article Synopsis
  • * It utilized a large sample of 2602 CRC patients, using the Hospital Anxiety and Depression Scale for measurement and analyzing survival data with advanced statistical methods.
  • * Results indicated that depression significantly increases the risk of poor survival outcomes, suggesting the need for regular screening and treatment of depressive symptoms in CRC patients to improve their overall prognosis.
View Article and Find Full Text PDF
Article Synopsis
  • Colorectal cancer affects both men and women, and diagnosis can be delayed due to various factors like absence of symptoms or lack of screening tests.
  • A study involving 1,688 patients across 22 Spanish hospitals aimed to assess whether delayed diagnosis impacts overall survival at five years.
  • Results showed that a diagnostic delay of more than 30 days did not worsen prognosis, while delays less than 30 days were linked to shorter survival, suggesting that quicker diagnoses are often related to more severe cases.
View Article and Find Full Text PDF

Introduction: The diagnosis or treatment of breast cancer is sometimes delayed. A lengthy delay may have a negative psychological impact on patients. The aim of our study was to evaluate the sociodemographic, clinical and pathological factors associated with delay in the provision of surgical treatment for localised breast cancer, in a prospective cohort of patients.

View Article and Find Full Text PDF

The aim of this study is to determine the survival of patients with breast cancer treated with adjuvant chemotherapy (ACh) after the diagnosis by screening, taking comorbidity into account. This multicenter cohort study examined a population of patients taking part in four national screening programs for the early detection of breast cancer (localized or locally advanced), during the period 2000-2008. Of the 1248 cancers detected, 266 were prevalent (21.

View Article and Find Full Text PDF

Aims: the aim of this study was to examine the possible association between the type of hospital admission and subsequent survival of the patient, as well as the pathological features recorded in a large population of patients with colorectal cancer.

Methods: the study included 1,079 patients diagnosed with colon or rectal cancer in the Hospital Costa del Sol (Marbella, Spain). The relationship between patient survival rate and type of first admission to the hospital (elective or emergency admission) was assessed.

View Article and Find Full Text PDF

Triple negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study is to explore the clinical relevance of Lehmann TNBC subtypes by identifying any differences in response to neoadjuvant chemotherapy among them. We determined Lehmann subtypes by gene expression profiling in paraffined pre-treatment tumor biopsies from 125 TNBC patients treated with neoadjuvant anthracyclines and/or taxanes +/- carboplatin.

View Article and Find Full Text PDF

Purpose: The delayed diagnosis of colorectal cancer (CRC) may be attributable to sociodemographic characteristics, to aspects of tumour histopathology or to the functioning of the health system. We seek to determine which of these factors most influences prolonged patient-attributable delay (PPAD) in the diagnosis and treatment of CRC.

Materials And Methods: A prospective, multicentre observational study was conducted in 22 Spanish hospitals.

View Article and Find Full Text PDF

A prospective study was performed of patients diagnosed with colorectal cancer (CRC), distinguishing between colonic and rectal location, to determine the factors that may provoke a delay in the first treatment (DFT) provided.2749 patients diagnosed with CRC were studied. The study population was recruited between June 2010 and December 2012.

View Article and Find Full Text PDF

Introduction: Soft tissue sarcomas are heterogeneous tumors that are difficult to treat. Up to 50 percent of patients develop metastatic disease and require systemic chemotherapy. Ifosfamide and doxorubicin are the two most active agents.

View Article and Find Full Text PDF